Details of the Drug

General Information of Drug (ID: DM5E73H)

Drug Name

Revusiran

Indication

Disease Entry	ICD 11	Status	REF
Amyloidosis	5D00	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

siRNA drug

Sequence

>Subunit 1
UGGGAUUUCAUGUAACCAAGAX
>Subunit 2
UCUUGGUUACAUGAAAUCCCAUC

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transthyretin messenger RNA (TTR mRNA)	TTPOYU7	TTHY_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02319005) ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.